JP4174570B2 - Ｈｌａ−ｃ分子に結合する単離されたペプチドとその使用 - Google Patents

Ｈｌａ−ｃ分子に結合する単離されたペプチドとその使用 Download PDF

Info

Publication number
JP4174570B2
JP4174570B2 JP2002531161A JP2002531161A JP4174570B2 JP 4174570 B2 JP4174570 B2 JP 4174570B2 JP 2002531161 A JP2002531161 A JP 2002531161A JP 2002531161 A JP2002531161 A JP 2002531161A JP 4174570 B2 JP4174570 B2 JP 4174570B2
Authority
JP
Japan
Prior art keywords
hla
cells
peptide
cell
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002531161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004524271A (ja
JP2004524271A5 (https=
Inventor
サチャ ジンジャティック，
ロイド ジェイ． オールド，
ヤスヒロ ナガタ，
エルク ジャガー，
ヤオ−セン チェン，
アレキサンダー ナス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Publication of JP2004524271A publication Critical patent/JP2004524271A/ja
Publication of JP2004524271A5 publication Critical patent/JP2004524271A5/ja
Application granted granted Critical
Publication of JP4174570B2 publication Critical patent/JP4174570B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2002531161A 2000-09-26 2001-09-24 Ｈｌａ−ｃ分子に結合する単離されたペプチドとその使用 Expired - Fee Related JP4174570B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/670,456 US6506875B1 (en) 2000-09-26 2000-09-26 Isolated peptides which bind to HLA-C molecules and uses thereof
PCT/US2001/029920 WO2002026778A2 (en) 2000-09-26 2001-09-24 Isolated peptides which bind to hla-c molecules and uses thereof

Publications (3)

Publication Number Publication Date
JP2004524271A JP2004524271A (ja) 2004-08-12
JP2004524271A5 JP2004524271A5 (https=) 2005-06-09
JP4174570B2 true JP4174570B2 (ja) 2008-11-05

Family

ID=24690468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002531161A Expired - Fee Related JP4174570B2 (ja) 2000-09-26 2001-09-24 Ｈｌａ−ｃ分子に結合する単離されたペプチドとその使用

Country Status (9)

Country Link
US (2) US6506875B1 (https=)
EP (1) EP1320609B1 (https=)
JP (1) JP4174570B2 (https=)
CN (1) CN1253572C (https=)
AT (1) ATE325876T1 (https=)
AU (2) AU2001293051B2 (https=)
CA (1) CA2423481C (https=)
DE (1) DE60119552T2 (https=)
WO (1) WO2002026778A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888100B2 (en) * 1996-10-03 2011-02-15 Memorial Sloan-Kettering Cancer Research Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
WO2014207708A2 (en) 2013-06-28 2014-12-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
CN105085616A (zh) * 2014-05-23 2015-11-25 上海市普陀区中心医院 一种氨基酸序列及其应用
CN105085615A (zh) * 2014-05-23 2015-11-25 上海市普陀区中心医院 一种多肽序列及其应用
BR112017013574A2 (pt) 2014-12-23 2018-03-06 Verdon Daniel conjugados de aminoácido e peptídeo e usos dos mesmos
EP3419962A4 (en) 2016-02-26 2020-03-11 Auckland Uniservices Limited CONJUGATES OF AMINO ACIDS AND PEPTIDES AND CONJUGATION METHOD
WO2020178738A1 (en) * 2019-03-04 2020-09-10 University Health Network T cell receptors and methods of use thereof
MX2021010541A (es) 2019-03-04 2021-12-15 Univ Health Network Receptores de linfocitos t y metodos de uso de estos.
CN113795586B (zh) 2019-03-25 2026-03-27 大学健康网络 T细胞受体及其使用方法
CN120397921B (zh) * 2025-05-28 2025-12-02 江苏新恒鼎装备制造有限公司 一种具有自锁功能的船用曲轴红套升降平台

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013481A (en) * 1993-07-22 2000-01-11 Ludwig Institute For Cancer Research Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
US6251603B1 (en) * 1996-10-03 2001-06-26 Ludwig Institute For Cancer Research Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
AU9572098A (en) * 1997-10-08 1999-04-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel human cancer antigen ny eso-1/cag-3 and gene encoding same
JP2002509859A (ja) * 1998-01-23 2002-04-02 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ Ｈｌａ−ａ２９分子に結合する単離ポリペプチド、それらをコードする分子である核酸、およびそれらの使用
WO2000020445A2 (en) * 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
WO2001062917A1 (en) * 2000-02-22 2001-08-30 Ludwig Institute For Cancer Research Isolated genomic sequences which encode the ny-eso-1 cancer testis tumor antigen and uses thereof

Also Published As

Publication number Publication date
DE60119552T2 (de) 2007-04-19
US7009035B2 (en) 2006-03-07
CN1253572C (zh) 2006-04-26
CN1476480A (zh) 2004-02-18
JP2004524271A (ja) 2004-08-12
EP1320609B1 (en) 2006-05-10
US20030050451A1 (en) 2003-03-13
AU9305101A (en) 2002-04-08
HK1060594A1 (en) 2004-08-13
AU2001293051B2 (en) 2007-04-26
ATE325876T1 (de) 2006-06-15
EP1320609A2 (en) 2003-06-25
CA2423481C (en) 2008-06-10
WO2002026778A3 (en) 2003-02-13
DE60119552D1 (de) 2006-06-14
WO2002026778A2 (en) 2002-04-04
US6506875B1 (en) 2003-01-14
CA2423481A1 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
JP3433322B2 (ja) 腫瘍拒絶抗原先駆体をコード化する核酸分子
AU693664B2 (en) Isolated nonapeptides presented by HLA molecules, and uses thereof
US6379901B1 (en) Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA molecules
US7148326B2 (en) Tumor antigen
US5851523A (en) Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5591430A (en) Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
JPH09502863A (ja) Ｍｈｃ分子ｈｌａ−ｃ−クローン１０と複合体を形成する分離されたペプチドとその利用方法
Kawashima et al. Identification of GP100‐derived, melanoma‐specific cytotoxic T‐lymphocyte epitopes restricted by HLA‐A3 supertype molecules by primary in vitro immunization with peptide‐pulsed dendritic cells
JP2003502079A (ja) Ｈｌａクラスｉｉ分子により提示されるｍａｇｅ−ａ１ペプチド
JP4174570B2 (ja) Ｈｌａ−ｃ分子に結合する単離されたペプチドとその使用
US6384190B1 (en) Isolated decapeptides which bind to HLA molecules
US5629166A (en) Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-C-clone 10/MAGE-1 derived peptides, and methods for treating said individuals
AU2001293051A1 (en) Isolated peptides which bind to HLA-C molecules and uses thereof
JP2003512057A (ja) Ｍａｇｅ−ａ１２抗原ペプチド及びその利用
US6664232B1 (en) HLA-A2 restraint tumor antigen peptide originating in SART-1
US7488793B2 (en) Isolated peptide which binds to HLA-Cw*07 and uses thereof
US20030228308A1 (en) Isolated peptides which bind to HLA-Cw6 molecules and uses thereof
HK1060594B (en) Isolated peptides which bind to hla-c molecules and uses thereof

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060703

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080711

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080716

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080716

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110829

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110829

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120829

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120829

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130829

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees